Introduction and Aims: Obesity and its resulting metabolic disturbances are major health threats and are the main cause of nonalcoholic fatty liver disease (NAFLD). Comound C has been demonstrated to be not only an inhibitor of AMPK, but also has some actions independent of AMPK inhibition. In our previous studies, we unexpectedly found compound C is an anti-inflammatory and anti-NLRP3 inflammasome agent in vitro. The aim of this study was to investigate the effects of compound C on a mouse model of high-fat diet (HFD) (60 kcal% fat)-induced obesity and hepatosteatosis in vivo.

Methods: C57BL/6 mice were fed with either a standard or a HFD for 14 weeks. These mice were divided in three groups [Normal chow, HFD + Vehicle, and HFD + compound C (6 mg/kg i.p., once a day)] and treated for an additional 4 weeks. All animals were weighed weekly and food intakes measured twice weekly. Liver histology as well as pro-inflammatory gene expression in liver and white adipose tissue (WAT) were examined.

Results: There was a significant reduction in body-weight gain and daily food intake in compound C-treated group compared with HFD group (P < 0.05). Glucose tolerance test and insulin tolerance test showed that compound C increased glucose metabolism and alleviated insulin resistance compared with the HFD group. Histology analysis showed a significant reduction of hepatic steatosis and ballooning by compound C. To further characterize the activity of compound C, quantitative RT-PCR analysis of pro-inflammatory markers were performed, demonstrating that compound C significantly reduced IL-1β, IL-18, IL-6 and TNF-a gene expression in the liver as well as in the WAT (P < 0.01). Moreover, NLRP3 inflammasome which plays an important role in obesity and NAFLD was significantly decreased by compound C using western blot assay.

Conclusions: Taken together, these results suggest that compound C offers the potential as a novel therapy for obesity and NAFLD, probably by impairing NLRP3 inflammasome activation and the related inflammasion.

Disclosure

F. Wang: None. W. Yang: None. R. Xiang: None. J. Yuan: None. Y. Liu: None. K. Chen: None. Z. Mo: None.

© 2018 by the American Diabetes Association.
2018
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.